Pulmatrix, a Lexington, MA-based developer of aerosol drugs intended to treat and prevent the spread of respiratory ailments, has raised $3 million in a financing, Mass High Tech reports, citing a regulatory filing. A company spokeswoman says the financing is a bridge round in anticipation of a larger financing, but the firm isn’t commenting on the details of the deal. The six-year-old firm’s previous backers include Waltham, MA, venture firms 5AM Ventures and Polaris Venture Partners. Luke wrote about Pulmatrix in September when it emerged from stealth mode.
Author: Ryan McBride
Ryan is an award-winning business journalist who contributes to our life sciences and technology coverage. He was previously a staff writer for Mass High Tech, a Boston business and technology newspaper, where he and his colleagues won a national business journalism award from the Society of American Business Editors and Writers in 2008. In recent years, he has made regular TV appearances on New England Cable News.
Prior to MHT, Ryan covered the life sciences, technology, and energy sectors for Providence Business News. He graduated with honors from the University of Rhode Island in 2001 with a bachelor’s degree in communications. When he’s not chasing down news, Ryan enjoys mountain biking and skiing in his home state of Vermont.
View all posts by Ryan McBride
